A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Reason given: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns
Key facts
- Where
- Denver, Fayetteville, Grand Rapids, Nashville, Rogers, Sarasota, and Springdale, United StatesSee the 9 sites
- Phase
- Phase 1
Where in United States
- Presbyterian/St Lukes Medical CenterDenver, United StatesNo longer taking part
- Sarah Cannon Research Institute at HealthONEDenver, United StatesNo longer taking part
- Highlands Oncology GroupFayetteville, United StatesNo longer taking part
- START | MidwestGrand Rapids, United StatesNo longer taking part
- Sarah Cannon Research Institute- PharmacyNashville, United StatesNo longer taking part
- SCRI Oncology PartnersNashville, United StatesNo longer taking part
- Highlands Oncology GroupRogers, United StatesNo longer taking part
- Florida Cancer Specialists Sarasota Drug Development UnitSarasota, United StatesNo longer taking part
- Highlands Oncology GroupSpringdale, United StatesNo longer taking part
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT06580938
- Record updated
- 23 March 2026
- Original description
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body.Read full original descriptionShow less
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF PF-07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body.
This study is seeking participants who have any of the following cancer types:
* non-small cell lung cancer * colorectal cancer * bladder cancer * melanoma (a type of skin cancer) * kidney cancer * head and neck cancer Participants will receive the study medicine PF-07921585 alone or in combination with another study medicine called sasanlimab at the study clinic.
PF-07921585 will be given as an infusion into a vein or as shots under the skin, once every 3 weeks. Sasanlimab will be given as shots under the skin, also once every 3 weeks.
The experiences of participants receiving the study medicine will be studied to help see if the study medicine is safe and effective. Participants may receive study medicine for up to 2 years, depending on how the cancer responds to the study treatment. Participants may continue receiving study medicine after 2 years if there are any benefits from the study treatment. Participants will attend visits once every 3 weeks with the first 9 weeks having more frequent visits, to check the safety of the study treatment.
Inclusion: Participants aged ≥18 years or older at the time of informed consent; Tumor types and prior treatment requirements: Participants entering Parts 2 and 3 must have at least 1 measurable lesion; Part 1 and Part 2:; Eligible advanced/metastatic tumor types include NSCLC, urothelial carcinoma (UC), renal cell carcinoma (RCC), melanoma, head and neck squamous cell carcinoma (HNSCC), and microsatellite stable colorectal cancer (MSS-CRC). Participants must have demonstrated radiographic progression on standard treatment(s) for their cancer; Part 3:; Cohort 1: Participants with metastatic melanoma with resistance to checkpoint inhibitor therapy and BRAF/MEKi; Cohort 2: Participants with metastatic MSS-CRC; Cohort 3: Participants with previously untreated metastatic NSCLC; ECOG PS 0 or 1.
Exclusion: Participants with any other active malignancy within 3 years prior to enrollment; History of Grade ≥3 immune-related AE (irAE) or unresolved irAEs prior to first dose of study intervention. Exception: vitiligo and endocrinopathy that is controlled with hormonal therapy; History of venous thromboembolic event <12 weeks prior to starting study treatment; Participants who have undergone treatment with any investigational IL-12 agent; Active or history of clinically significant gastrointestinal (GI) disease; Active or history of interstitial lung disease or Grade ≥2 pneumonitis; Active or history of clinically significant autoimmune disease; Active bleeding disorder; Active, uncontrolled infections; Known or suspected hypersensitivity to, or severe allergic history of, human albumin or anti-PD-(L)1 therapy.